European Urology Journal

Overview
Identity
View All

publication venue for

Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis 2021
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. 78:834-844. 2020
Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. 77:311-317. 2020
Response of Primary Renal Cell Carcinoma to Systemic Therapy. 76:852-860. 2019
Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. 75:853-860. 2019
Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. 75:300-309. 2019
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. 75:100-110. 2019
Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis. 73:242-251. 2018
Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis. 73:236-241. 2018
Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. 70:372-381. 2016
Long-term Impact of Mode of Delivery on Stress Urinary Incontinence and Urgency Urinary Incontinence: A Systematic Review and Meta-analysis. 70:148-158. 2016
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. 69:980-983. 2016
Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44. 69:644-645. 2016
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. 69:634-641. 2016
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.. 69:634-641. 2016
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. 69:624-633. 2016
Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer. 69:177-178. 2016
Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.. 69:177-178. 2016
Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. 67:803-812. 2015
What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. 65:1211-1217. 2014
The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. 65:3-6. 2014
Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. 64:518-519. 2013
Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review. 64:421-430. 2013
Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. 63:717-723. 2013
Cost Effectiveness of Treatment Options for Early Prostate Cancer: Can We Put the Puzzle Pieces Together?. 63:411-412. 2013
Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. 61:363-369. 2012
Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363–9. 61:e4-e5. 2012
Maximizing Cure for Muscle-Invasive Bladder Cancer: Integration of Surgery and Chemotherapy. 59:978-984. 2011
Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience. 59:556-562. 2011
Re: Gunnar Aus, Christopher Chapple, Tomas Hanûs, et al. The European Association of Urology (EAU) Guidelines Methodology: A Critical Evaluation. Eur Urol 2009;56:859–64. 56:e21-e22. 2009
Systematic Review and Meta-Analysis of Robotic-Assisted versus Conventional Laparoscopic Pyeloplasty for Patients with Ureteropelvic Junction Obstruction: Effect on Operative Time, Length of Hospital Stay, Postoperative Complications, and Success Rate. 56:848-858. 2009
Testosterone and Prostate Cancer: Revisiting Old Paradigms. 56:48-56. 2009
Editorial Comment on: Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin Receptor. 55:450-451. 2009
Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney. 54:866-874. 2008
Editorial Comment on: Photodynamic Diagnosis in Urology: State-of-the-Art. 53:1149-1150. 2008

has subject area

1103 Clinical Sciences (FoR)
Urology & Nephrology (Science Metrix)